Drug intelligence / Profile preview

CLENZIDerm

Development stage: Unknown
Lead developer: Obagi
Modality: Small Molecules
Administration: Topical

Overview

CLENZIDerm is a commercial skincare system developed by Obagi Medical Products, which was later acquired by Valeant Pharmaceuticals International. It is designed for the topical treatment of acne, utilizing a combination of active pharmaceutical ingredients: Salicylic Acid and Benzoyl Peroxide. The system works by exfoliating the skin, unclogging pores, reducing inflammation, and targeting acne-causing bacteria.

Brand names: CLENZIDermCLENZIDerm M.D. System
Other names: Obagi CLENZIDerm M.D. System

Beyond the preview

Go deeper on CLENZIDerm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLENZIDerm.

Explore the full profile